OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
08/13/2026
Back to search
Official data from USPTO
ARALINQ
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
ARALINQ
ST13
US500000079417866Class
1, 5, 35, 42
Filing
79417866
Registration
8081808
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
08/13/2026
Classification
Registered
Trademark type
Word
Nice classes
1, 5, 35, 42
Filing date
10/16/2024
Registration date
12/30/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/30/2025
Last transaction
08/13/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
CH
Examiner
O'BRIEN, JENNIFER LYNN
Law office
N30
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Araris Biotech AG
Representatives
Catherine F Hoffman Baker Donelson Bearman Caldwell & Berko
Technical classification
Nice Classes
Class 1Class 5Class 35Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicalbiochemicalbiological and molecular genetic products intended for laboratory analysisindustry and science namelychemicals for use in industry and sciencebiochemical preparations for scientific purposesBiological preparations for use in industry and scienceassays and reagents for use in genetic research; bioactive reagents and compounds namelydiagnostic reagents and preparationsexcept for medical or veterinary use; peptide substrates for scientific purposes; peptide derivatives in the nature of peptide substrates for scientific purposesproteins in raw material form for scientific and medical researchglycans being chemicals for use in industry and sciencenucleotides for scientific and medical research uselipids used in the manufacture of cosmeticsbeveragesfood products and food supplementsmonoclonal antiobodies for scientific purposesantibody-active principle conjugates in the nature of antibody reagents used for the detection of antigens in cells and tissueother than for medical or vetinary purposesantibody fragments in the nature of antibody reagents used for the detection of antigens in cells and tissueother than for medical or veterinary purposesantibody derivatives in the nature of antibody reagents used for the detection of antigens in cells and tissueother than for medical or veterinary purposesnucleic acids other than for medical or veterinary purposesDNA being diagnostic preparations for in vitro testing for scientific useviral vectors for research purposes; chemicalbiochemicalbiologicalbiotechnological and molecular genetic preparations in the nature of assays and reagents for use in genetic research for industrial and scientific use; chemicalbiologicalbiotechnological and molecular genetic preparationsnamely polypeptides for in vitro research use and industrial proteins for reagent development or production for industrial and scientific applications; biological preparationsnamely polypeptides for in vetro research usepeptide derivatives in the nature of peptide substrates for scientific purposes and industrial proteins for laboratories and analysis for industrial and scientific applications; chemical and biochemical substances for use in the manufacture of pharmaceuticals.
Class 5
Pharmaceutical products namelypharmaceutical preparations for the treatment of oncologyimmunologyinflammationinfectious diseasescardiovascular and metabolism diseases; medical preparations for the treatment of oncologyimmunologyinflammationinfectious diseasescardiovascular and metabolism diseases; pharmaceuticals and medical preparations in the field of cancer therapy; biopharmaceuticals and medical preparations in the field of active antibody conjugates for the treatment of oncologyimmunologyinflammationinfectious diseasescardiovascular and metabolism diseases; chemicalbiologicalmolecular genetic and biochemical and biopharmaceutical products for medicalpharmaceutical usenamely synthetic peptides for the treatment of oncologyimmunologyinflammationinfectious diseasescardiovascular and metabolism diseasesdiagnostic preparations for medical or veterinary purposes in the nature of peptide derivatives being substatesproteins arrays for medical diagnosis purposesantibodies for medical purposesactive antibody conjugates being antibodies for medical purposesantibody fragments being antibodies for medical purposesantibody derivatives being antibodies for medical purposesnucleic acids for medical or veterinary purposesDNA being diagnostic preparations for in vitro testing for medical useviral vector vaccines; pharmaceutical products and substances being pharmaceutical preparations for the treatment of diseases and preparations for medical treatments of oncologyimmunologyinflammationinfectious diseasescardiovascular and metabolism diseases
Class 35
Providing busines information with respect to business contacts for research projects.
Class 42
Scientific and technological services as well as research work and design services relating theretoscientific research services provided by scientists dedicated to the chemical and technological study of biological molecules; scientificmedicalbiologicalmolecular geneticchemicalpharmaceutical and technological researchin the field of biochemistry or pharmacy; Scientific laboratory services of a biochemical or pharmaceutical laboratory ; industrial analysis and research services in the field of pharmaceutical science ; development and research experimentation of medicines; Medical and scientific researchnamely conducting preclinical and clinical trials for others; laboratory services for the benefit of third partiesMedical laboratory services; scientific research advisory services in the biochemicalbiological and molecular genetic fields; scientific research advice for the pharmaceutical industry sector; scientific research analysis services for medical and pharmaceutical research services in connection with the treatment of individuals; provision of scientific research information and results.
Publications
History of USPTO decisions and trademark events.
29 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/30/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/27/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
07/26/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/13/2026
FIMP
FINAL DISPOSITION PROCESSED
07/13/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/30/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/30/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
12/30/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/11/2025
PUBO
PUBLISHED FOR OPPOSITION
11/11/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/05/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/15/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
10/14/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/14/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
10/14/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/14/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/27/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/27/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/27/2025
RFNT
REFUSAL PROCESSED BY IB
05/04/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/15/2025
RFRR
REFUSAL PROCESSED BY MPU
04/15/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/08/2025
CNRT
NON-FINAL ACTION WRITTEN
03/07/2025
DOCK
ASSIGNED TO EXAMINER
03/01/2025
MAFR
APPLICATION FILING RECEIPT MAILED
02/28/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/28/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/27/2025
Continuous trademark protection
Get notified about every new filing that threatens ARALINQ or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.